Literature DB >> 5110030

4-Ketocyclophosphamide, a metabolite of cyclophosphamide. Formation, chemical and biological properties.

H J Hohorst, A Ziemann, N Brock.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1971        PMID： 5110030

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN： 0004-4172


× No keyword cloud information.
  6 in total

1.  Proton magnetic resonance studies of the decomposition of 4-hydroxycyclophosphamide, a microsomal metabolite of cyclophosphamide.

Authors:  E J Valente; K K Chan; K L Servis
Journal:  Pharm Res       Date:  1984-03       Impact factor: 4.200

2.  [The evaluation of the cyclophosphamide sensitivity of human tumours by determining the incorporation of tritiated uridine and thymidine into the nucleic acids of human tumor cells in vitro in presence of 4-hydroxycyclophosphamide (author's transl)].

Authors:  G Bastert; H Schmidt-Matthiesen; G Voelcker; G Peter; H J Hohorst
Journal:  Z Krebsforsch Klin Onkol Cancer Res Clin Oncol       Date:  1975-09-22

3.  Excretion patterns of alkylating metabolites in urine following cyclophosphamide treatment of tumor patients: influence of application route, dosage, liver and kidney function.

Authors:  G Saul; M Matthias; H Rose; I Pradel
Journal:  J Cancer Res Clin Oncol       Date:  1979-07-27       Impact factor: 4.553

4.  [Fluorometric determination of "activated" cyclophosphamide and ifosfamide in blood (author's transl)].

Authors:  G Voelcker; R Haeglsperger; H J Hohorst
Journal:  J Cancer Res Clin Oncol       Date:  1979-04-12       Impact factor: 4.553

5.  [In vitro assay for cyclophosphamide-sensitivity of human tumours: the effect of 4-hydro-peroxy-cyclophosphamide on the incorporation of 3H-uridine into the nucleic acids of human tumour cells (author's transl)].

Authors:  G Bastert; G Voelcker; G Peter; H Schmidt-Matthiesen; H J Hohorst
Journal:  Z Krebsforsch Klin Onkol Cancer Res Clin Oncol       Date:  1976-03-19

Review 6.  Clinical pharmacokinetics of cyclophosphamide.

Authors:  Milly E de Jonge; Alwin D R Huitema; Sjoerd Rodenhuis; Jos H Beijnen
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.